News
bioMérieux, a world leader in in vitro diagnostics, celebrated the opening of the company’s Molecular Genomic Innovation Center in Philadephia, PA, on September 18th. The new 32,000 sq. ft. facility is home to the xPRO™ Program, which has rapidly changed the landscape of food safety diagnostic capabilities by partnering directly with industry leaders to address unmet needs to streamline operational efficiencies and further public health.
Swipe to discover more
-
First-Half 2024 Results
Marcy l’Etoile (France), September 5th, 2024 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 4th under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2024. -
Diagnosing & Treating Sepsis: The Need for Speed
Reducing deaths from sepsis is directly dependent on identifying sepsis early and quickly beginning appropriate antimicrobial treatment. Fast and accurate diagnosis may also shorten the length of a hospital stay for patients and reduce the emergence of bacteria that are resistant to multiple antibiotics. -
France: the bioMérieux bioindustrial and R&D site of La Balme is diversifying
Two strategic infrastructures were inaugurated this year on the bioMérieux site of La Balme-les-Grottes (Isère, France): a plastic injection unit in June and a new-generation R&D building in September. The global specialist in in vitro diagnostics is continuing its investments in France, aiming to develop new solutions for public health worldwide.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19